Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2008 Nov;14(11):1279-87.
doi: 10.1016/j.bbmt.2008.08.014.

Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma

Lauri M Burroughs  1 , Paul V O'Donnell, Brenda M Sandmaier, Barry E Storer, Leo Luznik, Heather J Symons, Richard J Jones, Richard F Ambinder, Michael B Maris, Karl G Blume, Dietger W Niederwieser, Benedetto Bruno, Richard T Maziarz, Michael A Pulsipher, Finn B Petersen, Rainer Storb, Ephraim J Fuchs, David G Maloney
Affiliations
Comparative Study

Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma

Lauri M Burroughs et al. Biol Blood Marrow Transplant. 2008 Nov.

Abstract

We compared the outcome of nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) for patients with relapsed or refractory Hodgkin lymphoma (HL) based on donor cell source. Ninety patients with HL were treated with nonmyeloablative conditioning followed by HCT from HLA-matched related, n=38, unrelated, n=24, or HLA-haploidentical related, n=28 donors. Patients were heavily pretreated with a median of 5 regimens and most patients had failed autologous HCT (92%) and local radiation therapy (83%). With a median follow-up of 25 months, 2-year overall survivals, progression-free survivals (OS)/(PFS), and incidences of relapsed/progressive disease were 53%, 23%, and 56% (HLA-matched related), 58%, 29%, and 63% (unrelated), and 58%, 51%, and 40% (HLA-haploidentical related), respectively. Nonrelapse mortality (NRM) was significantly lower for HLA-haploidentical related (P=.02) recipients compared to HLA-matched related recipients. There were also significantly decreased risks of relapse for HLA-haploidentical related recipients compared to HLA-matched related (P=.01) and unrelated (P=.03) recipients. The incidences of acute grades III-IV and extensive chronic graft-versus-host disease (aGVHD, cGVHD) were 16%/50% (HLA-matched related), 8%/63% (unrelated), and 11%/35% (HLA-haploidentical related). These data suggested that salvage allogeneic HCT using nonmyeloablative conditioning provided antitumor activity in patients with advanced HL; however, disease relapse/progression continued to be major problems. Importantly, alternative donor stem cell sources are a viable option.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Incidences of (A) grade II-IV aGVHD, (B) grade III–IV aGVHD, and (C) extensive cGVHD according to donor type.
Figure 2
Figure 2
Incidences of relapse according to donor type.
Figure 3
Figure 3
Incidences of (A) OS, and (B) PFS according to donor type.
Figure 4
Figure 4
Incidences of NRM according to donor type.
See this image and copyright information in PMC

References

    1. Avivi I, Goldstone AH. Autologous stem cell transplantation in Hodgkin’s disease (review) Ann Oncol. 2002;13 Suppl. 1:122–127. - PubMed
    1. Horning SJ, Chao NJ, Negrin RS, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indices. Blood. 1997;89:801–813. - PubMed
    1. Lazarus HM, Loberiza FR, Jr, Zhang M-J, et al. Autotransplants for Hodgkin’s disease in first relapse or second remission: a report from the Autologous Blood and Marrow Transplant Registry (ABMTR) Bone Marrow Transplant. 2001;27:387–396. - PubMed
    1. Lazarus HM, Rowlings PA, Zhang MJ, et al. Autotransplants for Hodgkin’s disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 1999;17:534–545. - PubMed
    1. Tsai T, Goodman S, Saez R, et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant. 1997;20:859–863. - PubMed

Publication types

MeSH terms